Spyre Therapeutics Inc.
SYRE
Market Cap$1.48B
Close$
$0.24
98.6% downside
Current Fair Value
98.6% downsideOvervalued by 98.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.48 Billion |
|---|---|
| Enterprise Value | $1.44 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-49.12 |
| Beta | 2.93 |
| Outstanding Shares | 45,316,264 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.1 |
|---|---|
| PEG | -340.07 |
| Price to Sales | - |
| Price to Book Ratio | 1.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.72 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Spyre Therapeutics Inc.
83 employeesaeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant...